Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation 先健科技公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1302)

RESIGNATION AND APPOINTMENT OF NON-EXECUTIVE DIRECTORS AND

MEMBER OF REMUNERATION COMMITTEE

Mr. Martha has resigned as a non-executive Director and a member of the Remuneration Committee with effect from 27 August 2015.

Following the resignation of Mr. Martha, Mr. Cleary has been appointed as a non-executive Director and a member of the Remuneration Committee with effect from 27 August 2015.

RESIGNATION OF NON-EXECUTIVE DIRECTOR AND MEMBER OF REMUNERATION COMMITTEE

The board (the "Board") of directors (the "Directors") of LifeTech Scientific Corporation (the "Company", together with its subsidiaries, the "Group") hereby announces that Mr. MARTHA Geoffrey Straub ("Mr. Martha") has resigned as a non-executive Director and a member of the remuneration committee of the Board (the "Remuneration Committee") with effect from 27 August 2015 in order to devote more time to his other business and personal engagements.

Mr. Martha has confirmed that he has no disagreement with the Board. Both Mr. Martha and the Board are not aware of any matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the "Stock Exchange").

The Board hereby expresses its gratitude to Mr. Martha for his valuable efforts and contributions to the Company during his tenure of office with the Company.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND MEMBER OF REMUNERATION COMMITTEE

The Board hereby further announces that following the resignation of Mr. Martha, Mr. CLEARY Christopher Michael ("Mr. Cleary") has been appointed as a non-executive Director and a member of the Remuneration Committee with effect from 27 August 2015.

Mr. Cleary, aged 55, holds a bachelor degree in Biology from The Colorado College. Mr. Cleary has over 20 years of experience in capital market investment, merger and acquisitions, corporate management and business development. He is currently the Vice President of Corporate Development at Medtronic plc. ("Medtronic"), a substantial shareholder (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules")) of the Company. Prior to joining Medtronic, Mr. Cleary worked at Alesia Capital Services LLC from 2011 to 2014 providing advisory and financial analysis services to Fortune 500 companies including Medtronic. From 1995 to 2011, Mr. Cleary worked at GE Capital Corporation ("GE Capital") leading merger & acquisition teams that closed acquisitions across more than 200 global transactions. Mr. Cleary received the GE Capital Chairman's Award for M&A excellence in 2005, and was a member of the General Electric Business Development Senior Leadership Council.

As at the date of this announcement, Mr. Cleary has not entered into any service contract nor letter of appointment with the Company. The remuneration of Mr. Cleary will be determined by the Board, after recommendation by the Remuneration Committee, at which Mr. Cleary will abstain. Further announcement will be made by the Company regarding the remuneration of Mr. Cleary once it has been determined by the Board.

It is proposed that the appointment of Mr. Cleary is for a term of three years. Pursuant to the Listing Rules and the articles of association of the Company, Mr. Cleary will hold office until the next following general meeting and shall be eligible for re-election at that meeting. Thereafter, he will be subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the Listing Rules and the articles of association of the Company.

Save as disclosed above, Mr. Cleary has not held any directorships in any other public companies the securities of which are listed in Hong Kong or overseas in the past three years nor did and does he hold any other positions in the Group in the past and at present. In addition, Mr. Cleary does not have any relationship with any other Directors, senior management or substantial shareholders or controlling shareholders of the Company.

As at the date of this announcement, Mr. Cleary does not have any interests in the shares or underlying shares of the Company pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information that is required to be disclosed under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters relating to the appointment of Mr. Cleary that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to welcome Mr. Cleary for joining as a member of the Board.

By Order of the Board

LifeTech Scientific Corporation

XIE Yuehui

Chairman Chief Fragutine Officer

Chairman, Chief Executive Officer and Executive Director

Hong Kong, 27 August 2015

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. WU Jianhui, Mr. MONAGHAN Shawn Del, Mr. JIANG Feng and Mr. CLEARY Christopher Michael being non-executive Directors; and Mr. LIANG Hsien Tse Joseph, Mr. ZHOU Gengshen and Mr. ZHOU Luming being independent non-executive Directors.